Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CXCR7
REST API REST API
Homo sapiens
CXCR7 is differentially expressed in 267 experiments: 143 organism parts: trachea, placenta, ... (141 more);, 174 disease states: normal, lung adenocarcinoma, ... (172 more);, 76 cell types 417 cell lines 36 compound treatments and 61 other conditions.
Synonyms CMKOR1, RDC1, GPR159
Orthologs ENSCING00000006352 (Ciona intestinalis)   ENSCING00000012511 (Ciona intestinalis)   Cxcr7 (Mus musculus)   cxcr7b (Danio rerio)   CXCR7 (2 of 2) (Danio rerio)   F6ZA54_CIOIN (Ciona intestinalis)   A4IF77_BOVIN (Bos taurus)   Cxcr7 (Rattus norvegicus)   cxcr7 (Xenopus laevis)   CXCR7_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, G-protein coupled receptor activity, negative regulation of apoptosis, G-protein coupled receptor protein signaling pathway, signal transducer activity, receptor activity, integral to membrane, chemokine-mediated signaling pathway, C-X-C chemokine receptor activity, interspecies interaction between organisms
InterPro Term GPCR_Rhodpsn_supfam, ATII_rcpt, 7TM_GPCR_Rhodpsn, Frt_met_rcpt, P2_purnocptor, RDC1_rcpt
UniProt Accession C9J5U9, P25106
Search EB-eye ENSG00000144476
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
SKBR3
2
E-MEXP-440, E-MTAB-62
A549
2
E-GEOD-6013, E-GEOD-3202
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF7
2
E-GEOD-5258, E-MTAB-37
411 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, ... (39 experiments)

Factor Value U/D Experiments
mononuclear cell
2
E-GEOD-6053, E-MEXP-66
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
secretory cell
1
E-GEOD-3998
ADC
1
1
E-GEOD-19188
keratinocyte
1
E-GEOD-3204
70 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-3678, E-MTAB-62, ... (52 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-62, E-MEXP-231, E-GEOD-2514, E-MTAB-37
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-TABM-26
neuroblastoma
2
E-MTAB-37, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
Raji Burkitt's lymphoma
2
E-AFMX-5, E-TABM-145
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
168 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-2639, E-GEOD-4668, E-GEOD-5741, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
keratinocyte growth factor
1
E-GEOD-7216
granulocyte-colony stimulating factor
1
E-GEOD-7400
Cxcl12
1
1
E-GEOD-7307
ponasterone A
1
E-GEOD-3113
baseline propofol
1
E-GEOD-4386
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-22513, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-MEXP-2283, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-TABM-868, E-GEOD-20115, E-TABM-601, E-GEOD-21243, ... (14 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, E-GEOD-19018, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2508, E-GEOD-19069, E-GEOD-7307

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.257 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM